RGNX:NASDAQREGENXBIO Inc. Analysis
Data as of 2026-06-19 - not real-time
$7.80
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Regenxbio is trading well below its 52‑week high and faces a bearish technical backdrop: the short‑term moving average sits beneath the medium‑term average, while the MACD histogram has turned positive but the overall trend remains downwards. Momentum indicators such as the RSI sit in a neutral zone, and the stock exhibits extreme price volatility and a beta that far exceeds the market, underscoring heightened price swings.
Fundamentally, the company is loss‑making with negative margins, a sizable debt load relative to equity, and no dividend, yet analysts maintain a "buy" consensus and price targets suggest more than double upside. The recent filing of a class‑action lawsuit adds a layer of legal risk that could pressure the price in the near term, even as market sentiment is currently in an "extreme greed" mode.
Fundamentally, the company is loss‑making with negative margins, a sizable debt load relative to equity, and no dividend, yet analysts maintain a "buy" consensus and price targets suggest more than double upside. The recent filing of a class‑action lawsuit adds a layer of legal risk that could pressure the price in the near term, even as market sentiment is currently in an "extreme greed" mode.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish moving‑average crossover
- Class‑action lawsuit creating legal uncertainty
- High short‑term price volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Analyst price targets indicating >200% upside
- Potential revenue upside from partnership pipelines
- Improving technical momentum with bullish MACD histogram
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Long‑term growth potential of gene‑therapy platform
- Strategic collaborations with major pharma partners
- Undervalued valuation relative to long‑run target prices
Key Metrics & Analysis
Financial Health
Revenue Growth-92.80%
P/E Ratio-2.8
ROE-196.43%
ROA-38.53%
Debt/Equity1178.24
P/B Ratio19.1
Op. Cash Flow$-233778000
Free Cash Flow$-138978624
Industry P/E24.1
Technical Analysis
TrendBearish
RSI56.9
Support$5.79
Resistance$8.73
MA 20$6.73
MA 50$7.95
MA 200$10.34
MACDBullish
VolumeIncreasing
Fear & Greed Index92.14
Valuation
Target Price$23.82
Upside/Downside205.36%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta2.21
Volatility165.02%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.